ATAGI update following weekly COVID-19 meeting – 2 February 2022

An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 2 February 2022.

Date published:
General public

Latest recommendation updates:

  • ATAGI provided advice on Pfizer boosters for individuals aged 16-17 years.

Recent ATAGI considerations

On Wednesday 2 February 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation.  As at 2 February 2022, over 50 million doses of COVID-19 vaccines have been administered in Australia. ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible.

Boosters for adolescents aged 16-17 years

ATAGI  recommends a booster vaccination with Comirnaty (Pfizer) COVID-19 vaccine, for all adolescents aged 16-17 years who have previously received any TGA approved or recognised vaccines for their primary vaccine schedule. This booster dose is available from 3 months after receiving their last primary dose.

The Pfizer vaccine is the only brand currently registered for use as a booster dose in this age group. ATAGI will update this advice if other vaccines are approved.

Full details of ATAGI’s advice is available.

Upcoming ATAGI considerations

ATAGI is continuing to monitor evidence on the effectiveness of vaccine boosters and national vaccination coverage rates.

COVID-19 vaccine safety

The ATAGI COVID-19 Safety Group will meet again this week to monitor known and emerging serious adverse events following immunisation and other safety issues in the delivery of COVID-19 vaccines. The ATAGI COVID-19 Safety Group provides regular updates to the ATAGI COVID-19 Working Group. The Therapeutic Goods Administration (TGA) Weekly Report provides a detailed breakdown of adverse events following immunisation.

Resources and recent statements

ATAGI recommends review of the following key resources:

More information can be found on the Department of Health website, with resources for both providers and patients.

Help us improve

If you would like a response please use the enquiries form instead.